Decitabine
Based on 177 publication(s) in Google Scholar
Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell Apoptosis. Decitabine has potent anticancer activity.
For research use only. We do not sell to patients.
- Purity: 99.87%
- CAS No.: 2353-33-5
- Formula: C8H12N4O4
- Molecular Weight:228.21
-
Storage:
4°C, protect from light
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
Publications Citing Use of MedChemExpress (MCE) Decitabine
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Science. 2026 Mar 12;391(6790):1130-1137. [Abstract]
- Cell. 2024 Apr 25;187(9):2288-2304.e27. [Abstract]
- Cancer Discov. 2024 Oct 4;14(10):1860-1878. [Abstract]
- Ann Rheum Dis. 2019 Oct;78(10):1420-1429. [Abstract]
- Nat Cell Biol. 2026 Apr;28(4):812-827. [Abstract]
- Cancer Res. 2026 Mar 5. [Abstract]
- Cancer Res. 2023 Nov 15;83(22):3813-3826. [Abstract]
- Nat Commun. 2024 May 21;15(1):4327. [Abstract]
- Nat Commun. 2023 Jan 10;14(1):18. [Abstract]
- ACS Nano. 2025 Jan 14;19(1):837-851. [Abstract]
- J Adv Res. 2025 May 21:S2090-1232(25)00358-3. [Abstract]
- Mol Cell. 2023 Dec 7;83(23):4370-4385.e9. [Abstract]
- Theranostics. 2021 Mar 20;11(11):5605-5619. [Abstract]
- Theranostics. 2020 Sep 15;10(25):11444-11461. [Abstract]
- J Clin Invest. 2025 Jun 2;135(11):e187490. [Abstract]
- J Exp Clin Cancer Res. 2024 May 30;43(1):152. [Abstract]
- Adv Sci (Weinh). 2025 Oct 20:e07908. [Abstract]
- Adv Sci (Weinh). 2025 Feb;12(5):e2408323. [Abstract]
- Adv Sci (Weinh). 2024 Oct;11(38):e2404693. [Abstract]
- Cell Rep Med. 2026 Feb 18:102630. [Abstract]
- Cell Rep Med. 2025 Apr 15;6(4):102053. [Abstract]
- Cell Rep Med. 2024 Jun 18;5(6):101592. [Abstract]
- Cell Rep Med. 2024 Jun 18;5(6):101580. [Abstract]
- Sci Adv. 2024 Apr 19;10(16):eadi1782. [Abstract]
- Neuro Oncol. 2023 Jan 5;25(1):82-96. [Abstract]
- Chem Eng J. 2025 Mar 15.
- Chem Eng J. 2024 Jul 15.
- J Control Release. 2025 Jun 10:382:113658. [Abstract]
- Cell Death Dis. 2026 Feb 26;17(1):275. [Abstract]
- Cell Death Dis. 2026 Jan 31;17(1):189. [Abstract]
- Cell Death Dis. 2023 Feb 11;14(2):106. [Abstract]
- Cell Death Dis. 2023 Jan 25;14(1):59. [Abstract]
- Pharmacol Res. 2023 Jan:187:106590. [Abstract]
- Cell Death Dis. 2022 Dec 24;13(12):1070. [Abstract]
- Pharmacol Res. 2022 Jun;180:106244. [Abstract]
- Cell Death Dis. 2021 Jun 23;12(7):642. [Abstract]
- Cell Death Dis. 2019 Feb 20;10(3):169. [Abstract]
- Cancer Lett. 2025 Aug 29:633:218010. [Abstract]
- Cancer Lett. 2022 Nov 1:548:215904. [Abstract]
- J Immunother Cancer. 2024 Mar 1;12(3):e008054. [Abstract]
- J Allergy Clin Immunol. 2019 Jun;143(6):2038-2051.e12. [Abstract]
- Hemasphere. 2026 Jan 15;10(1):e70289. [Abstract]
- EBioMedicine. 2026 May:127:106239. [Abstract]
- Acta Pharmacol Sin. 2026 May 18. [Abstract]
- Acta Pharmacol Sin. 2025 Aug 19. [Abstract]
- Acta Biomater. 2025 Jul 1:201:591-603. [Abstract]
- Acta Pharmacol Sin. 2022 Feb;43(2):457-469. [Abstract]
- J Orthop Translat. 2026 Jan 22.
- Proc Natl Acad Sci U S A. 2024 Apr 2;121(14):e2321611121. [Abstract]
- Oncogene. 2021 Apr;40(15):2711-2724. [Abstract]
- Oncogene. 2020 Aug;39(33):5507-5519. [Abstract]
- Leukemia. 2024 Oct;38(10):2210-2224. [Abstract]
- Int J Biol Macromol. 2025 Sep 5;327(Pt 2):147473. [Abstract]
- Int J Biol Macromol. 2025 May;306(Pt 3):141678. [Abstract]
- Int J Biol Macromol. 2025 May 8;311(Pt 4):144060. [Abstract]
- Int J Biol Macromol. 2025 Mar:295:139450. [Abstract]
- Int J Nanomedicine. 2024 Jul 16:19:7165-7183. [Abstract]
- NPJ Breast Cancer. 2023 Aug 11;9(1):66. [Abstract]
- Sens Actuators B Chem. 2023 Dec 4, 135097.
- Clin Chem. 2019 Dec;65(12):1522-1531. [Abstract]
- Free Radic Biol Med. 2024 Sep:222:288-303. [Abstract]
- Free Radic Biol Med. 2024 Aug 1:220:139-153. [Abstract]
- Clin Transl Med. 2026 Mar;16(3):e70638. [Abstract]
- Cancer Immunol Res. 2025 Apr 10. [Abstract]
- ACS Appl Mater Interfaces. 2026 Jun 24;18(24):33542-33558. [Abstract]
- Stem Cell Res Ther. 2025 Feb 21;16(1):79. [Abstract]
- Cell Rep. 2022 Oct 25;41(4):111561. [Abstract]
- Cell Prolif. 2021 Jul;54(7):e13072. [Abstract]
- Int J Radiat Oncol Biol Phys. 2023 Feb 1;115(2):440-452. [Abstract]
- Int J Oncol. 2025 Jan;66(1):4. [Abstract]
- J Invest Dermatol. 2020 Dec;140(12):2442-2454.e5. [Abstract]
- Biochem Pharmacol. 2026 Mar 15:249:117903. [Abstract]
- Cell Mol Life Sci. 2026 Feb 9;83(1):103. [Abstract]
- Biochem Pharmacol. 2026 Apr:246:117709. [Abstract]
- Cell Mol Life Sci. 2025 Jan 6;82(1):36. [Abstract]
- Biochem Pharmacol. 2024 Aug:226:116348. [Abstract]
- Cancer Gene Ther. 2023 Jun;30(6):855-865. [Abstract]
- Mol Metab. 2026 Jun 17:110:102402. [Abstract]
- Breast Cancer Res. 2024 Mar 11;26(1):44. [Abstract]
- RSC Adv. 2021 Dec 3;11(61):38907-38914. [Abstract]
- J Clin Transl Hepatol. 2024 Nov 28;12(11):917-929. [Abstract]
- Nutrients. 2022 Jun 16;14(12):2508. [Abstract]
- Eur J Pharmacol. 2025 Sep 15:1003:177942. [Abstract]
- Clin Epigenetics. 2025 Aug 15;17(1):142. [Abstract]
- Clin Epigenetics. 2025 Jul 7;17(1):120. [Abstract]
- Respir Res. 2025 May 10;26(1):179. [Abstract]
- Clin Epigenetics. 2024 Oct 14;16(1):140. [Abstract]
- Clin Epigenetics. 2024 Jul 23;16(1):97. [Abstract]
- Int Immunopharmacol. 2025 Sep 6:165:115445. [Abstract]
- Int Immunopharmacol. 2023 Oct 10;124(Pt B):111014. [Abstract]
- Int J Mol Sci. 2022 Aug 22;23(16):9481. [Abstract]
- Int J Mol Sci. 2022 Feb 14;23(4):2117. [Abstract]
- Int Immunopharmacol. 2021 Jul:96:107820. [Abstract]
- Inflammation. 2025 Jan 10. [Abstract]
- Front Cell Dev Biol. 2021 Mar 15:9:647527. [Abstract]
- Chem Biol Interact. 2026 May 27:112177. [Abstract]
- Bioorg Chem. 2022 Jul;124:105800. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Dec 13;1872(3):168132. [Abstract]
- Mol Med Rep. 2025 Sep;32(3):253. [Abstract]
- Cancer Sci. 2026 May 18. [Abstract]
- Sci Rep. 2025 Jul 1;15(1):21070. [Abstract]
- Sci Rep. 2025 Jul 9;15(1):24614. [Abstract]
- Am J Pathol. 2025 Jun 24:S0002-9440(25)00207-X. [Abstract]
- Sci Rep. 2025 Apr 16;15(1):13119. [Abstract]
- Stem Cell Rev Rep. 2021 Jun;17(3):938-951. [Abstract]
- Int J Cancer. 2021 Apr 1;148(7):1743-1755. [Abstract]
- Sci Rep. 2020 Sep 16;10(1):15201. [Abstract]
- Sci Rep. 2019 Jun 3;9(1):8171. [Abstract]
- Cancers (Basel). 2022 Nov 28;14(23):5854. [Abstract]
- Cancers (Basel). 2020 Oct 16;12(10):3009. [Abstract]
- Cancers (Basel). 2019 Dec 9;11(12):1984. [Abstract]
- Mol Cell Biochem. 2025 Mar;480(3):1845-1863. [Abstract]
- Cell Signal. 2023 Jun:106:110642. [Abstract]
- Rheumatology (Oxford). 2022 Aug 3;61(8):3471-3480. [Abstract]
- J Cell Mol Med. 2021 Jun;25(11):5070-5081. [Abstract]
- Prog Neurobiol. 2021 Jun:201:102028. [Abstract]
- iScience. 2025 Dec 3;29(1):114327. [Abstract]
- ACS Infect Dis. 2025 Oct 30. [Abstract]
- Mol Oncol. 2021 May;15(5):1566-1583. [Abstract]
- Bioengineering (Basel). 2025 Oct 19;12(10):1121. [Abstract]
- Aquaculture. 2023: 739234.
- Nanomedicine. 2023 Jan:47:102627. [Abstract]
- J Virol. 2026 Apr 21;100(4):e0179325. [Abstract]
- BMC Cancer. 2023 Jan 25;23(1):87. [Abstract]
- Cancer Res Commun. 2026 Jun 1;6(6):1509-1521. [Abstract]
- J Cell Physiol. 2023 Mar;238(3):610-630. [Abstract]
- Viruses. 2022 Jul 7;14(7):1485. [Abstract]
- Epigenetics. 2026 Dec;21(1):2606983. [Abstract]
- Genomics. 2025 Mar;117(2):111016. [Abstract]
- Mol Carcinog. 2023 Aug;62(8):1119-1135. [Abstract]
- Cell Biol Int. 2022 Sep;46(9):1399-1408. [Abstract]
- Int J Biochem Cell Biol. 2022 Jan:142:106117. [Abstract]
- Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
- Cell Biol Int. 2020 Feb;44(2):603-609. [Abstract]
- J Cancer. 2021 Jan 1;12(3):874-884. [Abstract]
- J Steroid Biochem Mol Biol. 2025 Jul 28:254:106839. [Abstract]
- J Appl Toxicol. 2023 Aug;43(8):1214-1224. [Abstract]
- Biomol Biomed. 2025 Aug 27. [Abstract]
- Gene. 2022 Aug 30:837:146689. [Abstract]
- Thorac Cancer. 2019 Jun;10(6):1388-1394. [Abstract]
- Biochem Biophys Res Commun. 2025 Sep 8:778:152305. [Abstract]
- Biochem Biophys Res Commun. 2025 Jul 8:769:151971. [Abstract]
- Onco Targets Ther. 2018 Sep 10:11:5631-5646. [Abstract]
- Exp Ther Med. 2022 Jul 5;24(3):561. [Abstract]
- Oncol Lett. 2024 May 1;28(1):295. [Abstract]
- Genes Genomics. 2022 Jul;44(7):801-812. [Abstract]
- Respir Physiol Neurobiol. 2023 Jul:313:104060. [Abstract]
- Biomed Res. 2026;47(3):89-101. [Abstract]
- bioRxiv. 2026 May 26:2026.05.22.726988. [Abstract]
- bioRxiv. 2026 Feb 18:2026.02.16.706212. [Abstract]
- bioRxiv. 2026 Jan 23:2026.01.22.701139. [Abstract]
- bioRxiv. 2025 Sep 21.
- Res Sq. 2025 Sep 18.
- Dartmouth College. 2025.
- University of Szeged. 2025.
- Uppsala University. 2025.
- bioRxiv. 2025 Jul 12:2025.07.08.663754. [Abstract]
- SSRN. 2025 May 18.
- bioRxiv. 2025 May 24.
- Patent. US20250152731A1.
- bioRxiv. 2025 Mar 17:2025.03.14.642839. [Abstract]
- Research Square Preprint. 2024 Aug 19.
- SSRN. 2025 Jan 27.
- bioRxiv. 2024 August 18.
- bioRxiv. 2024 Jan 16.
- bioRxiv. 2023 Oct 1.
- Research Square Print. 2023 Mar 21.
- Research Square Print. September 20th, 2022.
- J Oncol. 2022 Jun 23;2022:8724933. [Abstract]
- Biomed Pharmacother. 2022 Mar:147:112662. [Abstract]
- Oxid Med Cell Longev. 2022 Mar 29;2022:2371807. [Abstract]
- bioRxiv. February 15, 2022.
- Research Square Preprint. 2021 May.
- Research Square Preprint. 2020 Jul.
- Universität Duisburg-Essen. 2019 Aug.
- Patent. US20180263995A1.
-
RT-PCR
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
WB
-
IF
All DNA Methyltransferase Isoforms
More
Biological Activity
|
DNMT1 |
DNMT3A |
DNMT3B |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| LoVo | IC50 |
21.9 μM
Decitabine
|
Compound was tested for its inhibitory activity against LoVo cells.
Compound was tested for its inhibitory activity against LoVo cells.
|
[PMID: 24874286] |
| SW111 | IC50 |
24.2 μM
Decitabine
|
Compound was tested for its inhibitory activity against SW111 cells.
Compound was tested for its inhibitory activity against SW111 cells.
|
[PMID: 24874286] |
Decitabine treatment significantly inhibits cell growth of SNU719, NCC24 and KATOIII 96 hours after exposure to decitabine. Decitabine induces G2/M arrest and apoptosis in EBVaGC, inhibits invasion ability, and up-regulates E-cadherin expression for EBVaGC[1].
Only high concentrations (10 μM) Decitabine (0.1-1 μM; 24-72 hours) results in a G2 phase arrest, which is accompanied by a reduction of cells in G1 phase[3].
Decitabine up-regulates DCTPP1 and dUTPase expression in HeLa cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT116 cells
-
Concentration:0.1, 1, 10 µM
-
Incubation Time:24, 48, 72 hours
-
Result:Only high drug concentrations (10 µM) resulted in a G2 phase arrest, which was accompanied by a reduction of cells in G1 phase.
Decitabine (1.0 mg/kg; i.p.; once daily for 5 consecutive days) leads to regression of EL4 tumors established in C57BL/6 Mice[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice (bearing EL4 cells)[6]
-
Dosage:1.0 mg/kg
-
Administration:Intraperitoneal injection; once daily for 5 consecutive days
-
Result:Caused continuous tumor regression even after Decitabine treatment was stopped.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2353-33-5
-
Appearance Solid
-
Molecular Weight 228.21
-
Formula C8H12N4O4
-
Color White to off-white
-
SMILES
O[C@H]1C[C@H](N2C(N=C(N)N=C2)=O)O[C@@H]1CO
-
Synonyms
5-Aza-2'-deoxycytidine; 5-AZA-CdR; NSC 127716
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
Publications (177)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Science
2026 Mar 12;391(6790):1130-1137. PMID: 41411409 -
Cell
Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells. [Abstract]2024 Apr 25;187(9):2288-2304.e27. PMID: 38565142
Decitabine purchased from MedChemExpress. Usage Cited in: Cell. 2024 Apr 25;187(9):2288-2304.e27. [Abstract]
SLC6A6 mRNA levels in the indicated cells treated with decitabine (1 μM for 3 days).
-
Cancer Discov
CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype Specific Vulnerability in IDH2- and TET2-Mutant Cells. [Abstract]2024 Oct 4;14(10):1860-1878. PMID: 38819218 -
Ann Rheum Dis
2019 Oct;78(10):1420-1429. PMID: 31239244
Decitabine purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2019 Oct;78(10):1420-1429. [Abstract]
Western blot of PPARγ from mouse chondrocytes treated with IL-1β (10 ng/mL) for 24 hours in absence or presence 5Aza of various doses (0, 1, 5 and 10 µM).
Decitabine purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2019 Oct;78(10):1420-1429. [Abstract]
Western blot of PPARγ, MMP13, Aamts5, Aggrecan and Collagen2 from Sham, DMM and 5Aza-treated mouse joint tissues (0.35 mg/kg; intraperitoneal injection daily; 10 weeks).
-
Nat Cell Biol
TOLLIP targets GSDME-NT-carrying endocytic vesicles for autophagy to regulate pyroptosis and chemotherapy efficacy. [Abstract]2026 Apr;28(4):812-827. PMID: 41803502 -
Cancer Res
METTL3 Methylation Induces Decay of Endogenous Retroelement Transcripts to Promote Tumor Immune Evasion. [Abstract]2026 Mar 5. PMID: 41784625 -
Cancer Res
SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer. [Abstract]2023 Nov 15;83(22):3813-3826. PMID: 37695044 -
Nat Commun
Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. [Abstract]2024 May 21;15(1):4327. PMID: 38773088 -
Nat Commun
Age-related matrix stiffening epigenetically regulates α-Klotho expression and compromises chondrocyte integrity. [Abstract]2023 Jan 10;14(1):18. PMID: 36627269 -
ACS Nano
Chimeric Peptide-Engineered Polyprodrug Enhances Cytotoxic T Cell Response by Inducing Immunogenic Cell Death and Upregulating Major Histocompatibility Complex Class I. [Abstract]2025 Jan 14;19(1):837-851. PMID: 39731541 -
J Adv Res
Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysis. [Abstract]2025 May 21:S2090-1232(25)00358-3. PMID: 40409464 -
Mol Cell
CPT1A induction following epigenetic perturbation promotes MAVS palmitoylation and activation to potentiate antitumor immunity. [Abstract]2023 Dec 7;83(23):4370-4385.e9. PMID: 38016475 -
Theranostics
HDAC1 and 2 regulate endothelial VCAM-1 expression and atherogenesis by suppressing methylation of the GATA6 promoter. [Abstract]2021 Mar 20;11(11):5605-5619. PMID: 33859766 -
Theranostics
Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress. [Abstract]2020 Sep 15;10(25):11444-11461. PMID: 33052225 -
J Clin Invest
2025 Jun 2;135(11):e187490. PMID: 40454483 -
J Exp Clin Cancer Res
Unveiling the role of HP1α-HDAC1-STAT1 axis as a therapeutic target for HP1α-positive intrahepatic cholangiocarcinoma. [Abstract]2024 May 30;43(1):152. PMID: 38812060 -
Adv Sci (Weinh)
Morphine Tolerance Gated through EZH2-Mediated Suppression of Trpc5 in Spinal GABAergic Interneurons in Male Mice. [Abstract]2025 Oct 20:e07908. PMID: 41111460 -
Adv Sci (Weinh)
Sequential Release HydroLipo System for STING Gene Epigenetic Reprogramming and Immune Activation in Glioblastoma. [Abstract]2025 Feb;12(5):e2408323. PMID: 39661716 -
Adv Sci (Weinh)
Methuosis Inducer SGI-1027 Cooperates with Everolimus to Promote Apoptosis and Pyroptosis by Triggering Lysosomal Membrane Permeability in Renal Cancer. [Abstract]2024 Oct;11(38):e2404693. PMID: 39119834 -
Cell Rep Med
HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer. [Abstract]2026 Feb 18:102630. PMID: 41713410 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 15;6(4):102053. PMID: 40187357 -
Cell Rep Med
A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. [Abstract]2024 Jun 18;5(6):101592. PMID: 38843841 -
Cell Rep Med
Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia. [Abstract]2024 Jun 18;5(6):101580. PMID: 38776913 -
Sci Adv
RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cells. [Abstract]2024 Apr 19;10(16):eadi1782. PMID: 38630819 -
Neuro Oncol
2023 Jan 5;25(1):82-96. PMID: 35727735 -
-
-
J Control Release
Engineered vesicular cancer vaccines for immunosuppressive microenvironment reversion and in situ vaccine generation. [Abstract]2025 Jun 10:382:113658. PMID: 40122241 -
Cell Death Dis
2026 Feb 26;17(1):275. PMID: 41748545 -
Cell Death Dis
SLC46A1 deficiency-mediated folate restriction suppresses colorectal cancer progression through epigenetic-transcriptional reprogramming. [Abstract]2026 Jan 31;17(1):189. PMID: 41620398 -
Cell Death Dis
2023 Feb 11;14(2):106. PMID: 36774339 -
Cell Death Dis
Characterization of circSCL38A1 as a novel oncogene in bladder cancer via targeting ILF3/TGF-β2 signaling axis. [Abstract]2023 Jan 25;14(1):59. PMID: 36697384 -
Pharmacol Res
Oroxylin A regulates cGAS DNA hypermethylation induced by methionine metabolism to promote HSC senescence. [Abstract]2023 Jan:187:106590. PMID: 36464146 -
Cell Death Dis
UHRF1-mediated ferroptosis promotes pulmonary fibrosis via epigenetic repression of GPX4 and FSP1 genes. [Abstract]2022 Dec 24;13(12):1070. PMID: 36566325 -
Pharmacol Res
Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma. [Abstract]2022 Jun;180:106244. PMID: 35550167 -
Cell Death Dis
TXNIP, a novel key factor to cause Schwann cell dysfunction in diabetic peripheral neuropathy, under the regulation of PI3K/Akt pathway inhibition-induced DNMT1 and DNMT3a overexpression. [Abstract]2021 Jun 23;12(7):642. PMID: 34162834 -
Cell Death Dis
ZFP57 suppress proliferation of breast cancer cells through down-regulation of MEST-mediated Wnt/β-catenin signalling pathway. [Abstract]2019 Feb 20;10(3):169. PMID: 30787268 -
Cancer Lett
Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer. [Abstract]2025 Aug 29:633:218010. PMID: 40886822 -
Cancer Lett
KIF17 maintains the epithelial phenotype of breast cancer cells and curbs tumour metastasis. [Abstract]2022 Nov 1:548:215904. PMID: 36089118 -
J Immunother Cancer
Mitochondria-targeted photodynamic therapy triggers GSDME-mediated pyroptosis and sensitizes anti-PD-1 therapy in colorectal cancer. [Abstract]2024 Mar 1;12(3):e008054. PMID: 38429070 -
J Allergy Clin Immunol
Early-life undernutrition reprograms CD4+ T-cell glycolysis and epigenetics to facilitate asthma. [Abstract]2019 Jun;143(6):2038-2051.e12. PMID: 30654047
Decitabine purchased from MedChemExpress. Usage Cited in: J Allergy Clin Immunol. 2019 Jun;143(6):2038-2051.e12. [Abstract]
Naive CD4+ T cells are stimulated with anti-CD3/CD28 in the presence of mock stimulant or Decitabine (5-aza-29-deoxycytidine; 1 µM). Real-time PCR analysis of Il4 and Il13 mRNA after 24 hours of stimulation and IL-4 and IL-13 concentrations in culture supernatants after 72 hours of stimulation are measured.
-
Hemasphere
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML. [Abstract]2026 Jan 15;10(1):e70289. PMID: 41551728 -
EBioMedicine
Interleukin-27 remodels the bone marrow niche to suppress B-cell development and leukaemia progression in mouse models. [Abstract]2026 May:127:106239. PMID: 41932204 -
Acta Pharmacol Sin
PGK1 epigenetically silences STING via DNMT1 and its knockdown synergizes with STING agonists in pancreatic cancer. [Abstract]2026 May 18. PMID: 42144444 -
Acta Pharmacol Sin
DNMT inhibition epigenetically restores the cGAS-STING pathway and activates RIG-I/MDA5-MAVS to enhance antitumor immunity. [Abstract]2025 Aug 19. PMID: 40830678 -
Acta Biomater
CD4+T cell membrane-based nanocomposites for enhanced dual epigenetic therapy in psoriasis. [Abstract]2025 Jul 1:201:591-603. PMID: 40460911 -
Acta Pharmacol Sin
2022 Feb;43(2):457-469. PMID: 33850273 -
-
Proc Natl Acad Sci U S A
NSUN5/TET2-directed chromatin-associated RNA modification of 5-methylcytosine to 5-hydroxymethylcytosine governs glioma immune evasion. [Abstract]2024 Apr 2;121(14):e2321611121. PMID: 38547058 -
Oncogene
2021 Apr;40(15):2711-2724. PMID: 33712705 -
Oncogene
DNA polymerase beta modulates cancer progression via enhancing CDH13 expression by promoter demethylation. [Abstract]2020 Aug;39(33):5507-5519. PMID: 32641859
Decitabine purchased from MedChemExpress. Usage Cited in: Oncogene. 2020 Aug;39(33):5507-5519. [Abstract]
Quantitative real-time PCR analysis of CDH13 expression after 5 μM Decitabine treatment.
-
Leukemia
GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. [Abstract]2024 Oct;38(10):2210-2224. PMID: 39117798 -
Int J Biol Macromol
DNA methylation subtypes dictate metastatic heterogeneity of osteosarcoma via distinct tumor-stromal interactions: Multi-omics profiling and decitabine validation. [Abstract]2025 Sep 5;327(Pt 2):147473. PMID: 40915448 -
Int J Biol Macromol
Histone acetylation activated-IGF2BP3 regulates cyclin D1 mRNA stability to drive cell cycle transition and tumor progression of hepatocellular carcinoma. [Abstract]2025 May;306(Pt 3):141678. PMID: 40037458 -
Int J Biol Macromol
Mechanism of UHRF1 protein macromolecule regulating ferroptosis in liver cancer: inhibition of GSTZ1 expression through DNA methylation. [Abstract]2025 May 8;311(Pt 4):144060. PMID: 40348248 -
Int J Biol Macromol
Genome-wide analysis reveals porcine LIFR regulated by DNA methylation promotes the implantation process via the STAT3 signaling. [Abstract]2025 Mar:295:139450. PMID: 39756743 -
Int J Nanomedicine
miR-493-5p Silenced by DNA Methylation Promotes Angiogenesis via Exosomes and VEGF-A-Mediated Intracellular Cross-Talk Between ESCC Cells and HUVECs. [Abstract]2024 Jul 16:19:7165-7183. PMID: 39050873 -
NPJ Breast Cancer
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. [Abstract]2023 Aug 11;9(1):66. PMID: 37567892 -
-
Clin Chem
Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records. [Abstract]2019 Dec;65(12):1522-1531. PMID: 31578215 -
Free Radic Biol Med
Cannabidiol mitigates radiation-induced intestine ferroptosis via facilitating the heterodimerization of RUNX3 with CBFβ thereby promoting transactivation of GPX4. [Abstract]2024 Sep:222:288-303. PMID: 38830513 -
Free Radic Biol Med
Inhibiting DNA methyltransferase DNMT3B confers protection against ferroptosis in nucleus pulposus and ameliorates intervertebral disc degeneration via upregulating SLC40A1. [Abstract]2024 Aug 1:220:139-153. PMID: 38705495 -
Clin Transl Med
Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy. [Abstract]2026 Mar;16(3):e70638. PMID: 41804750 -
Cancer Immunol Res
The TRIB2-DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy. [Abstract]2025 Apr 10. PMID: 40208240 -
ACS Appl Mater Interfaces
Nanoparticle-Based Mitochondrial Disruptor Drives Tumor-Selective Pyroptosis for Effective Colorectal Cancer Immunotherapy. [Abstract]2026 Jun 24;18(24):33542-33558. PMID: 42273718 -
Stem Cell Res Ther
Human dental follicle stem cell-derived exosomes reduce root resorption by inhibiting periodontal ligament cell pyroptosis. [Abstract]2025 Feb 21;16(1):79. PMID: 39985080 -
Cell Rep
OTUB2 exerts tumor-suppressive roles via STAT1-mediated CALML3 activation and increased phosphatidylserine synthesis. [Abstract]2022 Oct 25;41(4):111561. PMID: 36288705 -
Cell Prolif
EZH2-mediated inhibition of KLF14 expression promotes HSCs activation and liver fibrosis by downregulating PPARγ. [Abstract]2021 Jul;54(7):e13072. PMID: 34031939
Decitabine purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2021 Jul;54(7):e13072. [Abstract]
The indicated HSCs are subjected to DNMTs inhibitor (5‐azadC, 2 μM), G9a inhibitor (UNC0642, 2 μM) and pan‐HDAC inhibitor (ITF‐2357, 100 nM) for 48 h, or EZH2 inhibitor (EPZ‐6438, 10 μM) for 72h. KLF14 expression is measured by RT‐qPCR.
Decitabine purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2021 Jul;54(7):e13072. [Abstract]
The indicated HSCs are subjected to DNMTs inhibitor (5‐azadC, 2 μM), G9a inhibitor (UNC0642, 2 μM) and pan‐HDAC inhibitor (ITF‐2357, 100 nM) for 48 h, or EZH2 inhibitor (EPZ‐6438, 10 μM) for 72h. KLF14 expression is measured by Western blotting analyses.
-
Int J Radiat Oncol Biol Phys
Ionizing Radiation Triggers the Antitumor Immunity by Inducing Gasdermin E-Mediated Pyroptosis in Tumor Cells. [Abstract]2023 Feb 1;115(2):440-452. PMID: 35918054 -
Int J Oncol
MYBBP1A‑mediated IGFBP4 promoter methylation promotes epithelial‑mesenchymal transition and metastasis through activation of NOTCH pathway in liver cancer. [Abstract]2025 Jan;66(1):4. PMID: 39611481 -
J Invest Dermatol
EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma. [Abstract]2020 Dec;140(12):2442-2454.e5. PMID: 32360600
Decitabine purchased from MedChemExpress. Usage Cited in: J Invest Dermatol. 2020 Dec;140(12):2442-2454.e5. [Abstract]
In EZH2 mutant cells, after six days of drug treatment with both GSK126 and 0.5 μM Decitabine, Western blots shows complete elimination of H3K37me3 with reductions in DNMT1A, DNMT3A, and DNMT3B.
Decitabine purchased from MedChemExpress. Usage Cited in: J Invest Dermatol. 2020 Dec;140(12):2442-2454.e5. [Abstract]
In EZH2 mutant cells, after six days of drug treatment with both GSK126 and 0.5 μM Decitabine, Significant upregulation of RASSF5, EPAS1, ITGB2, and NDRG1 target gene expression is seen in EZH2 mutant cell lines.
-
Biochem Pharmacol
Ticagrelor reverses multidrug resistance in breast cancer by inhibiting PI3K/AKT/mTOR pathway and suppressing ABCB1 expression and function. [Abstract]2026 Mar 15:249:117903. PMID: 41846011 -
Cell Mol Life Sci
ZNF711 promotes enzalutamide resistance through transcriptional and epigenetic modification of the androgen receptor signaling pathway. [Abstract]2026 Feb 9;83(1):103. PMID: 41656388 -
Biochem Pharmacol
DNMT1 knockdown mitigates sepsis-induced myocardial dysfunction by preventing TFAM-mediated mitochondrial DNA cytosolic escape and subsequent cGAS-STING to regulate macrophage M2 polarization. [Abstract]2026 Apr:246:117709. PMID: 41544860 -
Cell Mol Life Sci
Downregulation of FcRn promotes ferroptosis in herpes simplex virus-1-induced lung injury. [Abstract]2025 Jan 6;82(1):36. PMID: 39760769 -
Biochem Pharmacol
2024 Aug:226:116348. PMID: 38852642 -
Cancer Gene Ther
LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling. [Abstract]2023 Jun;30(6):855-865. PMID: 36782047 -
Mol Metab
Venetoclax and hypomethylating agents synergize to increase cell death and metabolic remodeling in acute B-lymphoblastic leukemia cells. [Abstract]2026 Jun 17:110:102402. PMID: 42309255 -
Breast Cancer Res
UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5. [Abstract]2024 Mar 11;26(1):44. PMID: 38468288 -
RSC Adv
Design and synthesis of water-soluble grifolin prodrugs for DNA methyltransferase 1 (DNMT1) down-regulation. [Abstract]2021 Dec 3;11(61):38907-38914. PMID: 35493211 -
J Clin Transl Hepatol
GPX4 Promoter Hypermethylation Induced by Ischemia/Reperfusion Injury Regulates Hepatocytic Ferroptosis. [Abstract]2024 Nov 28;12(11):917-929. PMID: 39544244 -
Nutrients
Maternal High-Fat Diet Aggravates Allergic Asthma in Offspring via Modulating CD4+ T-Cell Differentiation. [Abstract]2022 Jun 16;14(12):2508. PMID: 35745240 -
Eur J Pharmacol
VOPP1, a determinant of the sensitivity of non-small cell lung cancer cells to NAE inhibitors. [Abstract]2025 Sep 15:1003:177942. PMID: 40651787 -
Clin Epigenetics
Deciphering the methylation landscape of long noncoding RNAs in hepatocellular carcinoma: a focus on LINC00942. [Abstract]2025 Aug 15;17(1):142. PMID: 40817218 -
Clin Epigenetics
2025 Jul 7;17(1):120. PMID: 40624511 -
Respir Res
Thioredoxin: a key factor in cold tumor formation and a promising biomarker for immunotherapy resistance in NSCLC. [Abstract]2025 May 10;26(1):179. PMID: 40349025 -
Clin Epigenetics
2024 Oct 14;16(1):140. PMID: 39402618 -
Clin Epigenetics
DNA methylation-mediated suppression of TUSC1 expression regulates the malignant progression of esophagogastric junction cancer. [Abstract]2024 Jul 23;16(1):97. PMID: 39044262 -
Int Immunopharmacol
RNF180 suppressed aggressiveness by degrading NOTCH1, TRIM24 and FOXC1, and chemoresistance by degrading ACC1 and ACLY in colorectal cancer. [Abstract]2025 Sep 6:165:115445. PMID: 40915184 -
Int Immunopharmacol
2023 Oct 10;124(Pt B):111014. PMID: 37832237 -
Int J Mol Sci
2022 Aug 22;23(16):9481. PMID: 36012763 -
Int J Mol Sci
DNA Methylation Mediates EMT Gene Expression in Human Pancreatic Ductal Adenocarcinoma Cell Lines. [Abstract]2022 Feb 14;23(4):2117. PMID: 35216235 -
Int Immunopharmacol
5-Aza-2-deoxycytidine alleviates the progression of primary biliary cholangitis by suppressing the FoxP3 methylation and promoting the Treg/Th17 balance. [Abstract]2021 Jul:96:107820. PMID: 34162167 -
Inflammation
Dnmt3a-mediated DNA Methylation Regulates P. gingivalis-suppressed Cementoblast Mineralization Partially Via Mitochondria-dependent Apoptosis Pathway. [Abstract]2025 Jan 10. PMID: 39789287 -
Front Cell Dev Biol
Long Non-coding RNA SENP3-EIF4A1 Functions as a Sponge of miR-195-5p to Drive Triple-Negative Breast Cancer Progress by Overexpressing CCNE1. [Abstract]2021 Mar 15:9:647527. PMID: 33791304 -
Chem Biol Interact
Sulfur mustard exposure induces inflammatory injury by Dnmt3b-mediated DNA methylation via oleic acid accumulation in Treg cells. [Abstract]2026 May 27:112177. PMID: 42208724 -
Bioorg Chem
Icariside II suppressed tumorigenesis by epigenetically regulating the circβ-catenin-Wnt/β-catenin axis in colorectal cancer. [Abstract]2022 Jul;124:105800. PMID: 35468415 -
Biochim Biophys Acta Mol Basis Dis
2025 Dec 13;1872(3):168132. PMID: 41397617 -
Mol Med Rep
2025 Sep;32(3):253. PMID: 40641109 -
Cancer Sci
Integrated Transcriptomic and Functional Analyses Reveal lncRNA-miRNA-mRNA Axis in AML Relapse After Allo-HSCT. [Abstract]2026 May 18. PMID: 42151054 -
Sci Rep
DNMT3B aggravated renal fibrosis in diabetic kidney disease via activating Wnt/β-catenin signaling pathway. [Abstract]2025 Jul 1;15(1):21070. PMID: 40595027 -
Sci Rep
The key regulation of LncRNA MALAT during reprogramming of primary mouse hepatocytes into insulin producing cells. [Abstract]2025 Jul 9;15(1):24614. PMID: 40634357 -
Am J Pathol
2025 Jun 24:S0002-9440(25)00207-X. PMID: 40571124 -
Sci Rep
Decitabine promotes the differentiation of poorly differentiated gastric cancer cells and enhances the sensitivity of NK cell cytotoxicity via TNF-α. [Abstract]2025 Apr 16;15(1):13119. PMID: 40240368 -
Stem Cell Rev Rep
Ubiquitin-Specific-Processing Protease 7 Regulates Female Germline Stem Cell Self-Renewal Through DNA Methylation. [Abstract]2021 Jun;17(3):938-951. PMID: 33151468 -
Int J Cancer
Oncometabolite L-2-hydroxyglurate directly induces vasculogenic mimicry through PHLDB2 in renal cell carcinoma. [Abstract]2021 Apr 1;148(7):1743-1755. PMID: 33320958 -
Sci Rep
A membrane transporter determines the spectrum of activity of a potent platinum-acridine hybrid anticancer agent. [Abstract]2020 Sep 16;10(1):15201. PMID: 32939009 -
Sci Rep
Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms. [Abstract]2019 Jun 3;9(1):8171. PMID: 31160638 -
Cancers (Basel)
Drug Repurposing Applications to Overcome Male Predominance via Targeting G2/M Checkpoint in Human Esophageal Squamous Cell Carcinoma. [Abstract]2022 Nov 28;14(23):5854. PMID: 36497337 -
Cancers (Basel)
Dichotomous Impact of Myc on rRNA Gene Activation and Silencing in B Cell Lymphomagenesis. [Abstract]2020 Oct 16;12(10):3009. PMID: 33081395 -
Cancers (Basel)
Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells. [Abstract]2019 Dec 9;11(12):1984. PMID: 31835431 -
Mol Cell Biochem
2025 Mar;480(3):1845-1863. PMID: 39283563 -
Cell Signal
Effect of STK3 on proliferation and apoptosis of pancreatic cancer cells via PI3K/AKT/mTOR pathway. [Abstract]2023 Jun:106:110642. PMID: 36871796 -
Rheumatology (Oxford)
Mechanism of DNA methylation-mediated downregulation of O6-methylguanine-DNA methyltransferase in cartilage injury of Kashin-Beck disease. [Abstract]2022 Aug 3;61(8):3471-3480. PMID: 34888649 -
J Cell Mol Med
RAS-association domain family 1A regulates the abnormal cell proliferation in psoriasis via inhibition of Yes-associated protein. [Abstract]2021 Jun;25(11):5070-5081. PMID: 33960627 -
Prog Neurobiol
DNMT3L promotes neural differentiation by enhancing STAT1 and STAT3 phosphorylation independent of DNA methylation. [Abstract]2021 Jun:201:102028. PMID: 33636226
Decitabine purchased from MedChemExpress. Usage Cited in: Prog Neurobiol. 2021 Jun:201:102028. [Abstract]
The TF changes induced by DNMT3L in these cells are not affected with Decitabine (10 µM; for 24 hours) treatment in most genes tested, except NEUROD2 and NEUROG2 as shown by qRTPCR.
-
iScience
Prognostic value of BTG1 for predicting decitabine sensitivity in de novo acute myeloid leukemia. [Abstract]2025 Dec 3;29(1):114327. PMID: 41503213 -
ACS Infect Dis
Targeting the Rift Valley Fever Virus Polymerase: Resistance Mechanisms and Structural Insights. [Abstract]2025 Oct 30. PMID: 41166549 -
Mol Oncol
The miR-19b-3p-MAP2K3-STAT3 feedback loop regulates cell proliferation and invasion in esophageal squamous cell carcinoma. [Abstract]2021 May;15(5):1566-1583. PMID: 33660414 -
Bioengineering (Basel)
Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]2025 Oct 19;12(10):1121. PMID: 41155119 -
-
Nanomedicine
Polylactic acid based polymeric nanoparticle mediated co-delivery of navitoclax and decitabine for cancer therapy. [Abstract]2023 Jan:47:102627. PMID: 36410699 -
J Virol
2026 Apr 21;100(4):e0179325. PMID: 41805193 -
BMC Cancer
IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways. [Abstract]2023 Jan 25;23(1):87. PMID: 36698167 -
Cancer Res Commun
p97 Inhibition Synergistically Enhances Hypomethylating Therapy through Targeting of PLK1 in Acute Myeloid Leukemia. [Abstract]2026 Jun 1;6(6):1509-1521. PMID: 42248070 -
J Cell Physiol
Identification of key events and regulatory networks in the formation process of primordial germ cell based on proteomics. [Abstract]2023 Mar;238(3):610-630. PMID: 36745473 -
Viruses
Inducible miR-150 Inhibits Porcine Reproductive and Respiratory Syndrome Virus Replication by Targeting Viral Genome and Suppressor of Cytokine Signaling 1. [Abstract]2022 Jul 7;14(7):1485. PMID: 35891465 -
Epigenetics
Silencing of optogenetic and chemogenetic transgenes in human iPSCs involves promoter methylation and methylation-independent mechanisms. [Abstract]2026 Dec;21(1):2606983. PMID: 41468306 -
Genomics
MEF2A promoter methylation negatively regulates mRNA transcription and affects myoblast physiological function in cattle. [Abstract]2025 Mar;117(2):111016. PMID: 40024578 -
Mol Carcinog
PRMT1 inhibition promotes ferroptosis sensitivity via ACSL1 upregulation in acute myeloid leukemia. [Abstract]2023 Aug;62(8):1119-1135. PMID: 37144835 -
Cell Biol Int
PIK3CB promotes oesophageal cancer proliferation through the PI3K/AKT/mTOR signalling axis. [Abstract]2022 Sep;46(9):1399-1408. PMID: 35842767 -
Int J Biochem Cell Biol
Etoposide-induced protein 2.4 ameliorates high glucose-induced epithelial-mesenchymal transition by activating adenosine monophosphate-activated protein kinase pathway in renal tubular cells. [Abstract]2022 Jan:142:106117. PMID: 34801707 -
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287 -
Cell Biol Int
Promoter hypermethylation of the CFTR gene as a novel diagnostic and prognostic marker of breast cancer. [Abstract]2020 Feb;44(2):603-609. PMID: 31721358 -
J Cancer
Identifying Key Genes for Nasopharyngeal Carcinoma by Prioritized Consensus Differentially Expressed Genes Caused by Aberrant Methylation. [Abstract]2021 Jan 1;12(3):874-884. PMID: 33403044 -
J Steroid Biochem Mol Biol
Mogroside V restores glycolytic function via LDHA promoter demethylation independent of alternative splicing in PCOS granulosa cells. [Abstract]2025 Jul 28:254:106839. PMID: 40738262 -
J Appl Toxicol
Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. [Abstract]2023 Aug;43(8):1214-1224. PMID: 36861143 -
Biomol Biomed
Decitabine suppresses tumor growth by activating mouse mammary tumor virus and interferon-β pathways. [Abstract]2025 Aug 27. PMID: 40874377 -
Gene
Regulating DNA methylation could reduce neuronal ischemia response and apoptosis after ischemia-reperfusion injury. [Abstract]2022 Aug 30:837:146689. PMID: 35750086 -
Thorac Cancer
Investigation of the effect of P14 promoter aberrant methylation on the biological function of human lung cancer cells. [Abstract]2019 Jun;10(6):1388-1394. PMID: 31017733 -
Biochem Biophys Res Commun
EPB41L3 as a prognostic biomarker suppressing cellular malignancy and correlating with the immune microenvironment in glioma. [Abstract]2025 Sep 8:778:152305. PMID: 40674816 -
Biochem Biophys Res Commun
Connectivity-map unveils Gemcitabine's efficacy in overcoming nelarabine resistance in T-cell acute lymphoblastic leukemia. [Abstract]2025 Jul 8:769:151971. PMID: 40354678 -
Onco Targets Ther
The downregulated long noncoding RNA DHRS4-AS1 is protumoral and associated with the prognosis of clear cell renal cell carcinoma. [Abstract]2018 Sep 10:11:5631-5646. PMID: 30254456 -
Exp Ther Med
Bioinformatics analysis of KLF2 as a potential prognostic factor in ccRCC and association with epithelial-mesenchymal transition. [Abstract]2022 Jul 5;24(3):561. PMID: 35978925 -
Oncol Lett
Apolipoprotein A-1 downregulation promotes basal-like breast cancer cell proliferation and migration associated with DNA methylation. [Abstract]2024 May 1;28(1):295. PMID: 38737975 -
Genes Genomics
2022 Jul;44(7):801-812. PMID: 35567715 -
Respir Physiol Neurobiol
2023 Jul:313:104060. PMID: 37031925 -
Biomed Res
2026;47(3):89-101. PMID: 42178241 -
bioRxiv
Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States. [Abstract]2026 May 26:2026.05.22.726988. PMID: 42244620 -
bioRxiv
Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models. [Abstract]2026 Feb 18:2026.02.16.706212. PMID: 41757027 -
bioRxiv
2026 Jan 23:2026.01.22.701139. PMID: 41648188 -
-
-
-
-
-
bioRxiv
2025 Jul 12:2025.07.08.663754. PMID: 40672312 -
-
-
-
bioRxiv
2025 Mar 17:2025.03.14.642839. PMID: 40166192 -
-
-
-
-
-
-
-
J Oncol
2022 Jun 23;2022:8724933. PMID: 35783158 -
Biomed Pharmacother
Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models. [Abstract]2022 Mar:147:112662. PMID: 35091237 -
Oxid Med Cell Longev
GSDME Increases Chemotherapeutic Drug Sensitivity by Inducing Pyroptosis in Retinoblastoma Cells. [Abstract]2022 Mar 29;2022:2371807. PMID: 35480866
Decitabine purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2022 Mar 29;2022:2371807. [Abstract]
The toxicity of decitabine to Y79 and WERI-RB-1 cells is detected by CCK-8 assay at different concentrations of Decitabine.
Decitabine purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2022 Mar 29;2022:2371807. [Abstract]
The mRNA expression of GSDME is detected using RT-PCR after treatment with different concentrations of Decitabine for 3 days (the cells were centrifuged, and decitabine is replaced every day).
Decitabine purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2022 Mar 29;2022:2371807. [Abstract]
The protein level of GSDME in cells is quantitatively analysed by western blot in Y79 and WERI-RB-1 cells after Decitabine (2 nM; 3 days) treatment.
Decitabine purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2022 Mar 29;2022:2371807. [Abstract]
The protein level of GSDME in cells is detected using immunofluorescence in Y79 and WERI-RB-1 cells after Decitabine (2 nM; 3 days) treatment.
-
-
-
-
-
Solvent & Solubility
DMSO : ≥ 50 mg/mL (219.10 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 20 mg/mL (87.64 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.95 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 10 mg/mL (43.82 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (558 KB)
- English - EN (558 KB)
- Français - FR (558 KB)
- Deutsch - DE (558 KB)
- Norwegian - NO (558 KB)
- Español - ES (558 KB)
- Swedish - SV (558 KB)
- Italian - IT (558 KB)
- Korean - KR (558 KB)
- Portuguese - PT (558 KB)
-
Handling Instructions (2659 KB)
References
[1]. Nakamura M, et al. Decitabine inhibits tumor cell proliferation and up-regulates E-cadherin expression in Epstein-Barr virus-associated gastric cancer. J Med Virol. 2016 Jul 19. [Content Brief]
[2]. Parker WB. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev. 2009 Jul;109(7):2880-93. [Content Brief]
[3]. Hagemann S, et al. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One. 2011 Mar 7;6(3):e17388. [Content Brief]
[4]. Requena CE, et al. The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine. Biochem J. 2016 Jun 20. [Content Brief]
[5]. Terse P, et al. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice. Int J Toxicol. 2014 Mar-Apr;33(2):75-85. [Content Brief]
[6]. Yu J, et al. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest. 2018 Jun 1;128(6):2376-2388. [Content Brief]
[7]. Wang LX, et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumorspecific cytotoxic T lymphocyte responses. PLoS One. 2013 May 9;8(5):e62924. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (protect from light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 4.3819 mL | 21.9096 mL | 43.8193 mL | 109.5482 mL |
| 5 mM | 0.8764 mL | 4.3819 mL | 8.7639 mL | 21.9096 mL | |
| 10 mM | 0.4382 mL | 2.1910 mL | 4.3819 mL | 10.9548 mL | |
| 15 mM | 0.2921 mL | 1.4606 mL | 2.9213 mL | 7.3032 mL | |
| 20 mM | 0.2191 mL | 1.0955 mL | 2.1910 mL | 5.4774 mL | |
| 25 mM | 0.1753 mL | 0.8764 mL | 1.7528 mL | 4.3819 mL | |
| 30 mM | 0.1461 mL | 0.7303 mL | 1.4606 mL | 3.6516 mL | |
| 40 mM | 0.1095 mL | 0.5477 mL | 1.0955 mL | 2.7387 mL | |
| 50 mM | 0.0876 mL | 0.4382 mL | 0.8764 mL | 2.1910 mL | |
| 60 mM | 0.0730 mL | 0.3652 mL | 0.7303 mL | 1.8258 mL | |
| 80 mM | 0.0548 mL | 0.2739 mL | 0.5477 mL | 1.3694 mL | |
| DMSO | 100 mM | 0.0438 mL | 0.2191 mL | 0.4382 mL | 1.0955 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.